Is attention-deficit hyperactivity disorder (ADHD) diagnosed in adults? An examination of US office-based physician visits, 1995-2000

International Journal of Pharmaceutical Medicine

Volumn 18, Issue 6, 2004, Pages 337-341

  Robison, Linda M ^a   Skaer, Tracy L ^a   Sclar, David A ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington Institute for Mental Illness Research and Training   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMBULATORY CARE; ARTICLE; ATTENTION DEFICIT DISORDER; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICAL CARE; MEDICAL DOCUMENTATION; PHYSICIAN; POPULATION GROWTH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; UNITED STATES;

EID: 28444488307     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200418060-00003     Document Type: Article

References (42)

1. Robison LM, Skaer TL, Sclar DA. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002; 16: 129-37
2. Robison LM, Sclar DA, Skaer TL. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr 1999; 38: 209-17
3. Swanson JM, Lerner M, Williams L. More frequent diagnosis of attention deficit-hyperactivity disorder [letter]. N Engl J Med 1995; 333: 944
4. Diller LH. The run on ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Cent Rep 1996; 26: 12-8
5. Drug Enforcement Administration. Yearly aggregate production quotas. Washington, DC: Drug Enforcement Administration Office of Public Affairs, 1995
6. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996; 98: 1084-8
7. Safer DJ, Krager JM. The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics 1994; 94: 462-4
8. Zito JM, Safer DJ, dosReis S, et al. Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull 1997; 33: 143-7
9. Zito JM, Safer DJ, dosReis S, et al. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 1999; 153: 1257-63
10. Zametkin AJ, Ernst M. Problems in the management of attention-deficit- hyperactivity disorder. N Engl J Med 1999; 340: 40-6
11. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci 2001; 931: 1-16
12. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ 2003; 18: 715-22
13. Pierce K. Attention-deficit/hyperactivity disorder in adults. Prim Psychiatry 2003; 10: 77-80
14. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998; 59 Suppl. 7: 4-16
15. Schweitzer JB, Cummins TK, Kant CA. Attention-deficit/hyperactivity disorder. Med Clin North Am 2001; 85: 757-77
16. Murphy K, Barkley RA. Attention deficit hyperactivity disorder in adults: comorbidites and adaptive impairments. Compr Psychiatry 1996; 37: 393-401
17. Robison LM, Sclar DA, Skaer TL. Attention-deficit/hyperactivity disorder among adults [letter]. N Engl J Med 1999; 340: 1767
18. Pary R, Lewis S, Matuschka PR, et al. Attention deficit disorder in adults. Ann Clin Psychiatry 2002; 14: 105-11
19. Wender PH. Attention-deficit hyperactivity disorder in adults. Psychiatr Clin North Am 1998; 21: 761-74
20. Murphy K. Adults with attention deficit hyperactivity disorder: assessment and treatment considerations. Semin Speech Lang 1996; 17: 245-53
21. National Center for Health Statistics. National Ambulatory Medical Care Surveys, 1995-2000 [online]. Available from URL: www.cdc.gov/nchs/about/major/ ahcd/ahcd1.htm [Accessed2005 Mar 14]
22. Bryant E, Shimizu I. Sampling design, sampling variance, and estimation procedures for the National Ambulatory Medical Care Survey. National Center for Health Statistics. Vital Health Stat 1988; 2: 1-39
23. US Public Health Service and Health Care Financing Administration. International classification of diseases. 9th rev. Clinical modification, volume 1. DHHS publication no. (PHS) 89-1260. Washington: Public Health Service, 1989
24. Food and Drug Administration. National Drug Code Directory. 1995 ed. Washington, DC: Public Health Service, 1995
25. Koch H, Campbell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 1982; 2: 1-90
26. Sclar DA, Robison LM, Skaer TL. Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992-1995. Harv Rev Psychiatry 1999; 7: 29-36
27. Skaer TL, Sclar DA, Robison LM. Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992-1997. Clin Ther 2000; 22: 1575-89
28. Skaer TL, Sclar DA, Robison LM. Complaints of insomnia in the USA 1995-1998: prevalence, psychiatric comorbidity and pharmacologic treatment patterns. Prim Care Psychiatry 2001; 7: 145-51
29. US Census Bureau. National population estimates for the 1990s: monthly postcensal resident population, by single year of age, sex, race, and Hispanic origin [online]. Available from URL: http://www.census.gov/population/www/ estimates/nat_90s_1.html [Accessed 2000 Aug 14]
30. Adler LA, Chua HC. Management of ADHD in Adults. J Clin Psychiatry 2002; 63 Suppl. 12: 29-35
31. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 78-85
32. Stern HP, Garg A, Stern TP. When children with attention-deficit/ hyperactivity disorder become adults. South Med J 2002; 95: 985-91
33. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52: 434-43
34. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792-8
35. Biederman J, Spencer T. Methylphenidate in treatment of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 6 Suppl. 1: S101-7
36. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41 Suppl. 2: 26S-49S
37. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63 Suppl. 12: 10-5
38. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 2000; 9: 711-26
39. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 2004; 292: 619-23
40. Faraone SV, Sergeant J, Gillberg C. The worldwide prevalence of ADHD: is it an American condition? W Psychiatry 2003; 2: 104-13
41. World Federation for Mental Health. ADHD: the hope behind the hype: how to make a difference when reporting on attention deficit hyperactivity disorder. Alexandria (VA): World Federation for Mental Health, 2003
42. Biederman J, Faraone SV. Attention deficit hyperactivity disorder: a worldwide concern. J Nerv Ment Dis 2004; 192: 453-4